CANF
Can-Fite BioPharma Ltd.
$3.25
-0.23 (-6.61%)
At close · Jul 8
Market Cap
$6.96M
Shares
2,142,547
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.25
Open$3.40
Day$3.25–3.55
52W$2.56–21.00
Avg vol 30d2.9M
Short int47K · 2.2% float · 1.5d
Short vol23%
DataJan 2020–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
+1%
above
RSI (14)
50
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−22%
trailing
YTD return
−19%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+1300% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.20% of float · ▼ -30.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — 13F breadth
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−40%
Y/Y
EPS growth
+45%
Y/Y
Free cash flow
$-9.0M
Balance sheet
$5.5M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
14.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+1300% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.20% of float · ▼ -30.6% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $3
Now $3 · 4%
52-wk high $21
vs 200-day avg -39%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CANF
this stock
Can-Fite BioPharma Ltd.
|
$6.96M | -18.8% | -8.3% | — | 2.2% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CANF | +9.4% | +5.5% | -21.5% | +9.4% | -18.8% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +9.6% | +4.7% | -28.9% | +9.6% | -28.1% |